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ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2,
or SARS-CoV-2) is the cause of the respiratory infection known as COVID-19. From an
immunopathological standpoint, coronaviruses such as SARS-CoV-2 induce increased
levels of a variety of T-helper 1 (Th1) and inflammatory cytokines and chemokines,
including interleukin-1 (IL-1), IL-6, CCL2 protein, and CXCL10 protein. In the absence
of proven antiviral agents or an effective vaccine, substances with immunomodula-
tory activity may be able to inhibit inflammatory and Th1 cytokines and/or yield an
anti-inflammatory and/or Th2 immune response to counteract COVID-19 symptoms
and severity. This report briefly describes the following four unconventional but
commercially accessible immunomodulatory agents that can be employed in clinical
trials to evaluate their effectiveness at alleviating disease symptoms and severity:
low-dose oral interferon alpha, microdose DNA, low-dose thimerosal, and phytocan-
nabinoids.
KEYWORDS COVID-19, SARS-CoV-2, immunomodulatory agents, interferon alpha,
phytocannabinoids, thimerosal
Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2, or SARS-CoV-2) is a recently discovered coronavirus capable of causing the 2019 to 2020
respiratory infection known as COVID-19. Symptoms range from fever and coughing to
pneumonia or severe respiratory distress (e.g., shortness of breath). It is related to the
coronaviruses responsible for severe acute respiratory syndrome (SARS) from 2002 to
2003 and Middle East respiratory syndrome (MERS), first reported in 2012. Worldwide,
over 8,400 people became sick with SARS, of whom over 800 died. For MERS, close to
2,500 cases have been detected, with about 850 related deaths (data from World Health
Organization and National Institutes of Health websites). COVID-19 is widespread and,
in the midst of this global pandemic, as of late April 2020, there were about three
million confirmed infections and over 200,000 deaths reported worldwide (for updates,
see the Johns Hopkins University coronavirus COVID-19 dashboard: https://www.arcgis
.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6). To date,
there have been no agents proven to be capable of countering the virus, and vaccine
candidates are in early clinical testing, with availability to the general public at least a
year away.
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From an immunological standpoint, coronaviruses cause increases in the levels of
T-helper 1 (Th1) cytokine interferon (IFN) gamma, of inflammatory cytokines such as
interleukin-1 (IL-1), IL-6, and IL-12, and of related cytokines and chemokines, including
IL-8, chemokine (C-C motif) ligand 2 (CCL2 protein, also known as monocyte chemoat-
tractant protein-1, or MCP-1) and C-X-C motif chemokine 10 (CXCL10 protein, also
known as interferon gamma-induced protein 10, or IP-10) (1–7). The “cytokine storm”
mediated by these inflammatory and Th1 cytokines activates monocytes/macrophages
and neutrophils and is responsible for the immunopathological consequences of the
infection. It is recognized that hyperinflammatory immune responses can result in
increased disease severity and mortality. Therefore, inhibition of the hyperinflammatory
response is a definitive drug therapy objective. It has been proposed that certain
biological response modifiers, notably, cytokines IL-37 and IL-38, have the potential to
inhibit proinflammatory cytokines such as IL-6 and/or to induce an anti-inflammatory
immune response or an immunomodulatory response that could counteract COVID-19
patients’ hyperinflammatory responses (8–10). However, the time it might take to
develop such cytokine products for the treatment of COVID-19 patients is unknown at
this time. There is an urgent need for substances that can potentially counter the
effects of SARS-CoV-2 and alleviate the symptoms and severity of COVID-19. In the
current situation, every avenue of health care that might be available to decrease
morbidity and disease symptoms and severity and promote survival may be worthy of
investigation. Accordingly, it is suggested that clinical trials could be conducted on
certain substances with immunomodulatory activity from the realm of complementary
and alternative medicine. These immunomodulatory agents, while unconventional in
nature, offer potential treatment advantages and could augment or possibly be used in
place of standard clinical treatments. Furthermore, these potential immunomodulatory
agents may be readily available for utilization in clinical trials sanctioned by the U.S.
Food and Drug Administration (FDA) or other government drug regulatory agencies.
This report discusses four such agents, which were selected based on our prior
research, conducted both independently and collaboratively. They are (i) low-dose oral
interferon alpha (IFN-alpha), (ii) microdose DNA, (iii) low-dose thimerosal, and (iv) oral
or inhalable (by inhaler, not by combustion) phytocannabinoids.
Low-dose oral IFN-alpha. IFN-alpha is a cytokine that is a known inducer of
antiviral immune responses. There have been commercially available, injectable ver-
sions of IFN-alpha (e.g., IFN-alpha-2b [Roferon]), approved by the FDA for use only in
cases of chronic hepatitis C and certain forms of cancer. IFN-alpha-2b is dosed at 3 to
9 million international units (IU) and has substantial side effects (see https://www.drugs
.com/pro/roferon-a.html). One other noteworthy use of IFN-alpha has been in the
treatment of Behcet’s disease, an inflammatory blood vessel disease with a cytokine
profile that has been characterized as Th1-like in nature (11). In contrast to formulations
such as IFN-alpha-2b, oral (oromucosal) administration of human or bovine IFN-alpha at
low doses of 50 to 200 units has been investigated as a potential antiviral strategy for
several decades. There have been substantial in vitro, in vivo, and human and veterinary
clinical research studies involving the use of low-dose oral IFN-alpha against infections
caused by herpes and influenza viruses, foot and mouth disease virus, and a variety of
bovine respiratory viruses (12–14). From a mechanistic standpoint, low concentrations
of IFN-alpha can regulate the expression of a variety of cytokine genes, chemokine
genes, and related genes involved in antiviral immune responses. In one such study
involving peripheral blood mononuclear cells (PBMCs) from calves treated with 50 or
200 units of oral IFN-alpha, the expression levels of 41 of 92 tested autoimmune and
inflammatory response-associated genes were significantly upregulated or downregu-
lated (15). Using the Kyoto Encyclopedia of Genes and Genomes (KEGG) online data-
base (https://www.genome.jp/kegg/), 12 of these genes were identified as involved in
cytokine-cytokine receptor interactions. What was particularly intriguing was that seven
of these genes (CSF1, CXCL12, FAS, IL2RA, IL6R, TNFRSF1A, and TNFSF13B) were
downregulated at the 50-U concentration, whereas five of these genes (IFNAR2, IL1A,
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IL1B, IL-10, and IL10RB) were upregulated at the 200-U concentration. Increased
production of cytokine IL-10 (encoded by the IL-10 gene) mediated by IFN-alpha was
a key finding in an in vitro study of PBMCs derived from Behcet’s disease patients (16).
The investigators related the effectiveness of administration of IFN-alpha in treatment
of diseases such as Behcet’s disease to changes in Th1 and inflammatory cytokine
levels. These data suggest that low-dose oral IFN-alpha can regulate the expression of
specific immune response genes and the production of specific cytokines or chemo-
kines that may be relevant to the alleviation of COVID-19 symptoms. While the use of
low-dose oral interferon as prophylaxis for influenza in a double-blind, FDA-authorized
clinical trial did not prevent acute respiratory illness in treated relative to control
individuals, it did reduce symptom severity and was seen as beneficial to a subpopu-
lation of patients (17). Currently, it is marketed as a nutraceutical under the trade name
of Paximune. Given the body of existing research and the unmet medical needs of
COVID-19 patients, plus a favorable safety profile at these dose levels, it is believed that
an FDA-authorized clinical trial of this substance specifically for reducing the symptoms
and severity of respiratory symptoms in COVID-19 patients could be conducted in
relatively short order.
Microdose DNA. Cystic fibrosis (CF) is a genetic disease characterized by abnormal,
viscous mucus secretions. The viscosity of these secretions results from the high
concentration of exogenous DNA that is released from necrotic neutrophils (18). This
observation resulted in the development of the DNA-degrading enzyme, DNase (dor-
nase alfa [Pulmozyme]) as a treatment for CF symptoms (19). Since the presence of
excessive neutrophils in the sputum of CF patients suggested an aberrant compensa-
tory immune response, it was hypothesized that the use of exogenous, sublingually
administered DNA can be applicable as a neutralization therapy. This hypothesis was
the basis for the development of a proprietary formulation of a low concentration of
DNA fragments derived from salmon sperm DNA, otherwise referred to as microdose
DNA (20, 21). The term “microdose” was applied based on its oral (sublingual) admin-
istration in microgram-range doses (0.6 g per dose, based on a 12 g/ml DNA
concentration and a drop volume of 50 l). It was hoped that sublingual dosing with
microdose DNA would decrease neutrophil necrosis and DNA release into the lungs,
thus decreasing sputum viscosity. Microdose DNA was first utilized in evidence-based
clinical testing of CF patients. This sublingual therapeutic approach subsequently was
extended to patients with other respiratory diseases and otitis media. The specific
mechanism(s) of action of microdose DNA has not been elucidated; at least five
different hypotheses have been postulated. Among these hypotheses are those pos-
iting the generation of beneficial immune responses through increases in levels of
anti-inflammatory cytokines and immunomodulatory changes in T-helper 1/T-helper 2
(Th1/Th2) cytokine ratios (21). There is some experimental evidence from in vivo studies
of dogs with kennel cough indicating that microdose DNA treatment increases levels of
the anti-inflammatory cytokine IL-4 (S. W. Mamber, unpublished data). It has also been
observed that the DNA fragments might contain oligodeoxynucleotides (ODNs) with
the CpG motif (CpG ODNs), which are known to stimulate an immune response to viral
infections (22). Under the clinical trial names HP-3 and ML-03, microdose DNA was
tested in three separate FDA-approved, placebo-controlled, double-blind phase II
clinical trials, one for the treatment of CF, one for chronic bronchitis, and one for
chronic obstructive pulmonary disease (COPD). There were only 17 treatment patients
and 20 patients on placebo in the CF clinical trial. Although the trials were underpow-
ered to achieve statistical significance, a trend toward improvement was observed for
three respiratory parameters. In the chronic bronchitis trial, 25 patients were adminis-
tered microdose DNA, with 24 patients on placebo. Among other endpoints, there was a
statistically significant improvement (P  0.007) in forced expiratory volume (FEF25–75%), a
measure of small-airway function. Finally, in the COPD clinical trial, there were 23
patients randomized to receive microdose DNA versus 25 on placebo. There was a
statistically significant outcome (P  0.019) in a key endpoint, the 6-min walk test (21).
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All three clinical trials demonstrated the potential of microdose DNA in improving
respiratory function in patients with different lung diseases. Moreover, there were no
safety issues apparent in these trials. Though it was not developed further as a
pharmaceutical agent for economic reasons, the current DNA-based therapeutic is
being marketed as a nutraceutical and is being sold commercially as Mucolyxir. The
combined evidence-based and clinical trial experiences with various respiratory ail-
ments, plus commercial availability, make microdose DNA a viable candidate to test in
clinical trials for treatment of COVID-19 respiratory symptoms.
Low-dose thimerosal. Thimerosal (alternatively, thiomersal) is an organomercury
compound that is commonly used as a vaccine preservative. With a typical concentra-
tion of 0.01%, a 0.5-ml dose of vaccine contains 50 g of thimerosal. Because of
controversy surrounding the presence of thimerosal in vaccines and neurological
diseases such as autism, the use of thimerosal in vaccines has been curtailed over
the past 20 years (see https://www.fda.gov/vaccines-blood-biologics/safety-availability
-biologics/thimerosal-and-vaccines). However, some researchers have been intrigued
by the possibility that very small doses of thimerosal (0.2 g, or 1/250 of the amount
present in a typical vaccine dose) can promote an antiviral immune response. In that
regard, low-dose thimerosal might be considered to be a hormetic, a substance that is
beneficial at low concentrations but inhibitory or toxic at higher concentrations. In
terms of background, in 1979 J. B. Miller reported that influenza vaccine could also be
used to treat herpesvirus infections (23). In studying the components of the influenza
vaccine, it was eventually determined that the antiherpes activity was not related to
any influenza virus component of the vaccine. Rather, it was the thimerosal that was
responsible (24). Further research indicated that low-dose thimerosal was not acting
directly against herpes virus, influenza virus, or other viruses. Instead, low-dose thime-
rosal might have been signaling an antiviral host response that is immunological in
nature. In separate studies, thimerosal has been shown to induce the Th2 immune
response and/or inhibit the production of proinflammatory cytokines and chemokines,
including IFN-gamma, IL-1 beta, IL-6, IL-12p70, and MCP-1 (25, 26). Furthermore, in vitro
gene expression profiling experiments with human diploid fibroblast cells indicated
that thimerosal at low concentrations (1.6 to 40 ng/ml) can regulate the expression of
specific cytokine, chemokine, and related immune response genes capable of mediat-
ing host immune responses to viral infections (Mamber, unpublished). Thimerosal can
inhibit herpesvirus activity, based on in vitro experiments showing viral plaque reduc-
tion in treated human keratinocytes, but this is believed to result from innate cellular
immune responses rather than from direct antiviral effects (V. Gurel, unpublished
results). Low-dose thimerosal is currently not commercially available. However, it has
been employed in two FDA-approved, randomized, double-blind, placebo-controlled
clinical trials to evaluate its safety and efficacy. The first trial, a phase lla study, evaluated
thimerosal for its ability to block progression to lesion in patients with recurrent oral
herpes caused by dental trauma, while the follow-up phase llb study evaluated the
same indication in patients with herpes caused by exposure to ultraviolet radiation.
While the individual clinical trials were underpowered and did not show statistically
significant outcomes, the outcome data pooled from the two studies that shared a
common endpoint did achieve statistical significance (Beech Tree Labs, unpublished
data). There has been little experience in employing low-dose thimerosal against
coronaviruses to date. However, the favorable safety profile and the simple formulation
and sublingual dosing of low-dose thimerosal make this an interesting candidate for a
clinical trial to determine if it can effectively alleviate COVID-19 symptoms and severity.
(To further ensure safety, in accordance with thimerosal-containing vaccine recommen-
dations by the FDA, low-dose thimerosal should not be administered to children under
6 years of age.)
Phytocannabinoids. Phytocannabinoids derived from Cannabis sativa, such as
cannabidiol (CBD) and 9-tetrahydrocannabinol (THC), have been shown to inhibit
inflammatory and Th1 cytokines and/or promote anti-inflammatory and Th2 immune
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responses both in vitro and in vivo (27–29). As COVID-19 represents a respiratory disease
with a dominant Th1 and inflammatory immune response profile, it has been postu-
lated that cannabinoids represent a class of compounds with the potential to alleviate
COVID-19 symptoms and severity by helping to decrease inflammation and restore a
Th1/Th2 balance in the immune system. THC, for example, has been shown to shift the
Th1/Th2 cytokine balance in human T cells to one favoring Th2 cytokines. Of particular
interest was the inhibition of IFN-gamma production (27). CBD decreased inflammation
in a mouse model of lung injury, with decreased production of proinflammatory
cytokines and chemokines, including IL-6 (28). In preliminary studies, an oil extract from
Cannabis sativa containing both CBD and THC upregulated Th2 and anti-inflammatory
genes such as the IL-4 gene (encoding IL-4) and the PPARG gene (encoding peroxisome
proliferator-activated receptor gamma) in human small-airway epithelial cells in vitro.
There were also certain genes involved in mucus overproduction or hypersecretion that
were downregulated. These included the CLCA1 gene (encoding chloride channel
accessory 1) and the CMA1 gene (encoding mast cell chymase 1) (29). Preliminary in
vivo testing in Caribbean vervet monkeys (Chlorocebus aethiops sabaeus) indicated that
the oil extract improved inspiratory lung functions (J. Osborn, University of Kentucky,
unpublished data). More research will be needed to determine which cannabinoid or
cannabinoid mixture might be effective in treating COVID-19 symptoms and at what
concentrations. The method of drug delivery is also a consideration. The use of
combustible products (i.e., smoking) is obviously contraindicated for patients with
acute respiratory distress. Oral ingestion would be the logical delivery method. How-
ever, an oil-based product may be suitable as the active pharmaceutical ingredient (API)
for direct inhalation therapy (e.g., utilization in handheld aerosol inhalers or by nebu-
lized vapor inhalation, which may be augmented with oxygen). API formulation incip-
ient propellants often use natural oil components. Such a formulation would offer a
convenient treatment method through delivery to the lungs.
Comment. The four substances described here do not have, or are not expected to
have, direct antiviral activity against SARS-CoV-2 in vivo. (Pending further research,
phytocannabinoids may be an exception, which actually would be a positive.) Rather,
they appear to be acting as immunomodulatory agents. Modulation of the immune
response may be achieved through inhibition of inflammatory cytokines and produc-
tion of anti-inflammatory cytokines; restoring the Th1/Th2 balance; or otherwise sig-
naling cells to produce therapeutically beneficial cytokines, chemokines, and related
proteins. Accordingly, such treatments may have the potential to alleviate the immu-
nopathological symptoms caused by SARS-CoV-2. On the basis of existing in vivo and
clinical experiences, the optimal time for use of these potential immunomodulatory
agents would be at the first signs of disease symptoms, when there would be a better
chance of reestablishing immune homeostasis. One further consideration is the poten-
tial disease-modifying utility that these immunomodulators might have in patients with
preexisting health conditions, including chronic respiratory diseases such as COPD.
Such patients may be at the highest risk for severe morbidity and mortality from
COVID-19. If formal clinical trials are not feasible, it is suggested that these substances
be investigated in an observational manner under principles of informed consent and
compassionate use.
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